Project Grant R35GM161660
- Federal Grant Award Summary The Trustees of Tufts College received a $256,616 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports the development of a comprehensive graph theory toolbox designed to analyze genetic interaction networks and identify redundant biological pathways. The research will establish a formal...
- Federal Project Grant Award Summary The Trustees of Tufts College received a $249,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 15, 2025, with a completion date of September 14, 2028. The research project, titled "Elucidating the Epigenetic Regulation of Extracellular Matrix and Virus-Induced Fibroblast Activation," investigates the molecular...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Harvard Medical School a Project Grant of $125,000.00 under the Biomedical Research and Research Training program (CFDA 93.859) on March 1, 2026, with a completion date of February 29, 2028. This award funds fundamental research to advance understanding of transcription-replication conflicts—harmful collisions between the cellular machinery responsible for transcription and DNA replication that can...
- Federal Grant Award Summary Award Details: The National Institute of General Medical Sciences (NIGMS) awarded a Project Grant of $617,007 to President and Fellows of Harvard College (Harvard Medical School) effective August 1, 2025, through June 30, 2030, under the Biomedical Research and Research Training program (CFDA 93.859). Research Objectives and Deliverables: This project investigates the molecular mechanisms of Non-Homologous End Joining (NHEJ), the primary DNA double-strand break repair...
- Federal Grant Award Summary Massachusetts Institute of Technology received a $149,264 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), awarded March 1, 2026, with completion targeted for September 24, 2028. The award funds structural investigations into the regulatory states of human ribonucleotide reductase (RNR), an essential enzyme for DNA synthesis and repair. The research utilizes cryogenic...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded a $425,333 Project Grant to the University of Massachusetts Boston, effective March 1, 2026, through February 28, 2031, under the Biomedical Research and Research Training program (CFDA 93.859). This research initiative investigates the cellular and molecular mechanisms governing stem and progenitor cell (SPC) development during tissue homeostasis and following injury. The project utilizes the...
- Federal Project Grant Award Summary The University of Massachusetts Boston received a $422,173 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective July 1, 2025 through June 30, 2030. The award funds fundamental basic research investigating cellular signaling networks that control organism development and tissue patterning. The research employs the fruit fly Drosophila as a model...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded $227,652 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Biomedical Research and Research Training program (CFDA 93.859) on June 26, 2026. The award supports a three-year research project (completion date: May 31, 2029) titled "Modeling the Cascade of Genome Rearrangements in the Ciliate Oxytricha Trifallax." The project delivers...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $613,838 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through February 28, 2031. The award supports fundamental research investigating the dynamic interactions between intracellular membranes and the cortical cytoskeleton, with a specific focus on elucidating the molecular mechanisms...
- Federal Grant Award Summary Boston University Medical Campus received a $439,148 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on March 13, 2026, with completion targeted for January 31, 2031. The award supports fundamental research to understand the regulation of mitochondrial deoxyribonucleic acid (DNA) packaging and gene expression, with specific focus on how cells regulate...
Award Details: The National Institute of General Medical Sciences (NIGMS) awarded Trustees of Tufts College a $392K Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) on May 11, 2026, with completion targeted for February 28, 2031. Research will be conducted at the awardee's facility in Medford, Massachusetts. Products and Services: This project grant funds fundamental research investigating DNA damage tolerance strategies and genome stability mechanisms at the organismal level. The research employs a Drosophila model system to advance understanding of translesion DNA polymerases' roles in double-strand break repair and lesion bypass pathways. Key deliverables include scientific discoveries regarding DNA polymerase theta's function in alternative end-joining repair, characterization of translesion synthesis bypass mechanisms in highly proliferative tissues, and identification of novel genes promoting tolerance to exogenous and endogenous DNA damage through forward genetic screening. The project builds on established findings regarding REV1 translesion polymerase scaffold protein function and SLX1/4 nuclease activity in damage tolerance pathways, with planned expansions into template switching and fork reversal mechanisms. These research outcomes will contribute foundational knowledge applicable to understanding cancer cell vulnerability to translesion polymerase inhibition and supporting development of potential therapeutic targets.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $392.0k | 5/12/26 |